Patrick Aisher

Patrick Aisher's work experience includes positions at various companies. Patrick is currently working as a Director at CEBINA Bridge Capital. In 2021, they also took on the role of an Investor at Danube Labs, where they focus on translating life science projects into future medicines. Additionally, they serve as a Director at SONECT and a Strategic Advisor and Investor at NativeWaves GmbH. In 2020, they became an Investor/Director at PreComb Therapeutics AG, an Investor at Araris Biotech AG, Imcheck Therapeutics, LAVA Therapeutics B.V., and Vico Therapeutics B.V. Furthermore, they work as an Investor at Artiria Medical, where they develop technologies for stroke treatment.

Patrick Aisher completed a BBA degree in Business Administration and Economics at Schiller International University Heidelberg, London Campus, from 1986 to 1990. Patrick then pursued a Master of Business Administration (MBA) program in Finance at Heriot-Watt University from 1995 to 1996. In 2004, they attended the Swiss Stock Exchange and studied Entrepreneurial Finance with a focus on regulatory aspects until 2008. Patrick then completed a Trust Management program in Trust Law at the Society of Trust & Estate Professionals in 2007-2008. In 2008-2009, they pursued the Swiss Advanced Certificate in Trust Management Program at Geneva Financial Centre/STEP, focusing on Advanced Trust Concept, Regulation, Estate Planning, and Taxation.